Abstract
To the Editor: We read with great interest the subgroup analyses of the Raloxifene use for the Heart (RUTH) trial.1 Although this post hoc analysis did not show benefit of raloxifene for any prespecified group, we believe that one particular subgroup, not defined in this study, may benefit from raloxifene in the reduction of coronary outcomes. Although RUTH did not show an overall benefit in postmenopausal women with established …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have